Patent intelligence · US
US 11357770
Method of treating immunoglobulin light chain amyloidosis
Method of treating immunoglobulin light chain amyloidosis
Patent details — US 11357770
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 14, 2022
- Expiration
- Jun 9, 2042
- Applicant
- Alterity Therapeutics Limited
- Claims
- 17
- CPC classes
- A61K, A61K31/47, A61K31/4709, A61P
Quick answer
US 11357770 (Method of treating immunoglobulin light chain amyloidosis) is held by Alterity Therapeutics Limited. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alterity Therapeutics Limited
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/47, A61K31/4709, A61P, A61P39/04, A61P43/00
More from Alterity Therapeutics Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11357770?
US 11357770 (Method of treating immunoglobulin light chain amyloidosis) is held by Alterity Therapeutics Limited. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11357770?
Alterity Therapeutics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11357770 expire?
Our index shows an expiration date of Jun 9, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.